According to the results, it is most likely that shikonin inhibits CAKI-2 and A-498 proliferation and migration by affecting the targets of the PTEN/PI3K/AKT pathway, revealing the possible effects of shikonin on the therapy of kidney cancer. This evidence concerns the gene AKT1 and kidney cancer.